



Contact:
Bill Enright
President & CEO
Phone: 205-909-3751
Email: enright@vaxin.com

FOR IMMEDIATE RELEASE

VAXIN ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS

Vaxin Strengthens Resources

Birmingham, Alabama – February 19, 2010 – Vaxin Inc., an emerging vaccine company today announced four appointments to the company's board of directors. The new directors include, Lyle A. Hohnke, Ph.D., General Partner, Tullis Dickerson & Company, who will serve as Chairman of the Board, David J. Drutz, M.D., President, Pacific Biopharma Associates; Ike W. Lee, Ph.D., President and Chief Executive Officer, AnC Bio Holdings; and Michael M. Rice, Managing Partner, DJE Advisors.

"We are thrilled to have assembled a board with such outstanding technical, financial, and operational experience," said Bill Enright, Chief Executive Officer of Vaxin. "The board's depth and breadth of knowledge are tremendous assets that will be invaluable as we continue to advance our pipeline of vaccine candidates and position them for commercial success."

Vaxin also announced that G. Michael Alder, a co-founder of Vaxin, and Kent R. Van Kampen, D.V.M., Ph.D., Chief Operating Officer (COO) of Vaxin, have resigned from the Board. Dr. Van Kampen will continue in his role as COO.

"The management and Board of Vaxin are deeply appreciative to Kent and Mike for the significant contributions they have made to Vaxin's growth and maturation," Mr. Enright added. "There are very few individuals with their scientific pedigree, entrepreneurial experience and track record in biotechnology and we thank them for their considerable contributions over the years. They have been thoughtful advisors and valued members of our management team and Board, and we look forward to continuing our long and valuable close association with each of them."

New Board Members:

David J. Drutz, M.D., is President of Pacific Biopharma Associates, LLC, a biotechnology consulting firm based in Chapel Hill, North Carolina and a co-founder and former General Partner of Pacific Rim Ventures Ltd., an international life science investment company based in Tokyo, Japan. Dr. Drutz's management experience includes tenures as VP Biological Sciences at Smith Kline & French Laboratories, VP Clinical Development at Daiichi Pharmaceutical

Corporation, and CEO of several biotechnology companies. Earlier in his career, Dr. Drutz was Professor of Medicine and Chief of the Division of Infectious Diseases at the University of Texas Health Science Center, San Antonio and prior to that appointment was Assistant Professor of Medicine and Chief of the Division of Infectious Diseases at the University of California, San Francisco/San Francisco General Hospital. Dr. Drutz received his M.D. from the University of Louisville School of Medicine in Louisville, Kentucky and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation.

Lyle A. Hohnke, Ph.D., is a General Partner of Tullis Dickerson & Company, a leading health care private equity group based in Greenwich, Connecticut, where he is responsible for identifying and structuring investments in life sciences, healthcare and biotechnology companies. Prior to joining Tullis Dickerson, Dr. Hohnke was Chairman and CEO of Diamond Animal Health, formerly an operating division of Bayer Animal Health, which produced animal vaccines and pharmaceuticals. In 1996, Dr. Hohnke merged the company with Heska Corporation, raising approximately \$42,000,000 from top-tier investors. He received his Ph.D. in physiology and his M.A. in biology from the University of Oregon.

Ike W. Lee, Ph.D., is the President and CEO of AnC Bio Holdings, a pharmaceutical company based in Seoul, South Korea. Prior to joining AnC Bio, Dr. Lee co-founded and was Managing Partner of Seoul-based Alopax Consulting. Earlier in his career, Dr. Lee served as a Research Associate and Instructor in the Cardiovascular Division of Beth Israel Deaconess Medical Center and Department of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Lee received his Ph.D. in molecular biology from the University of Georgia, in Athens, Georgia and his M.S. in microbiology from Yonsei University Graduate School, in Seoul, South Korea.

In October, 2009, Vaxin built upon its global business model by entering into a joint venture with AnC Bio to develop and manufacture its vaccines for use throughout Asia.

Michael M. Rice is Managing Partner of DJE Advisors, a consulting firm dedicated to the life sciences where he is responsible for providing strategic advice to biotechnology and pharmaceutical companies. Prior to founding DJE, Mr. Rice was Managing Director of the Life Sciences Investment Banking division of Canaccord Adams and before that he served as Managing Director, Head of Healthcare Equity Capital Markets at ThinkEquity Partners. In those positions, Mr. Rice successfully originated and completed equity financings in excess of \$1,300,000,000. He received his B.A. in Economics from the University of Maryland, in College Park, Maryland.

About Vaxin:

Vaxin Inc. is an emerging clinical stage vaccine company developing needle-free, single dose highly safe and effective vaccines. These molecular vaccines are safely administered either in the nose or on the skin, taking the battle against diseases to the immune system's front lines where the diseases are attacking, rather than injecting the vaccine inside the body where the body's immune response is actually weaker. This delivery mechanism also allows Vaxin's vaccines to be mass administered by personnel without sophisticated medical training.

As a vaccine delayed may be a vaccine denied, it is crucial to produce vaccines in a timely manner, especially in the event of a pandemic or bioterrorist attack. The company's technology platform provides a critical tool for the rapid production of vaccines against influenza, avian influenza and anthrax utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin's vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics.

Vaxin's unique technology was developed by Dr. De-chu C. Tang, Vaxin's scientific founder and Vice President of Research. Unlike current vaccines, which typically use a weakened form of the targeted disease, such as the influenza virus, Vaxin's molecular vaccines are created by inserting only a piece of the influenza virus (the gene encoding an antigen) into a benign delivery vehicle. This "Trojan Horse" method increases the safety of the vaccine and virtually eliminates the risk of a vaccine reverting to a disease causing agent. Needle-free, non-replicating, single-dose molecular vaccines also have many other advantages. Patients clearly prefer vaccines which are not injected because there is no fear of needles or the pain they can cause.

Vaxin's technology also has applications for animal health. Automated in ovo (in the egg) vaccination is the method of choice for the mass immunization of poultry because of the ease of administration and lower costs. Unlike most technologies that have been tried, Vaxin's technology safely introduces a protective vaccine into the egg without harming the embryo.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

#